Digitisation | May 21, 2026
Bristol Myers Squibb & Anthropic redraw biopharma with Claude-powered enterprise AI
BMS is moving beyond conversational AI into what it describes as “agentic” systems
BMS is moving beyond conversational AI into what it describes as “agentic” systems
In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
